Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BK-SE36/CpG malaria vaccine safety and immunogenicity study in malaria-exposed adults and children in Burkina Faso
PACTR201701001921166Unknown
- Sponsor
- Nobelpharma Co., Ltd.
- Start
- Sep 2017
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Trial of BK-SE36 and Rabies vaccine in malaria, sponsored by Nobelpharma Co., Ltd. Primary endpoint: Safety and reactogenicity restricted to serious or severe adverse events. Status: unknown.
02
Drugs
BK-SE36Rabies vaccine
03
Conditions
malaria
Beyond the preview
Go deeper on PACTR201701001921166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201701001921166.